Hi Mr. Ed,
I feel that Biotech has an excellent product, much better than their
glitazone competitors (WLA, BMY, SBH, LLY). All these drugs have liver toxicity problems (especially Resulin-WLA). The problem I see is this:
1. Bob R. Pres. He has too much on his plate, he needs to DELEGATE. It's
his "baby", and he is triing to handle too many aspects as a CEO. In doing this, I feel he is failing to properly inform shareholders, Wall Street, brokers, market makers, etc. of the companies progress, when it occurs. He is also a poor, very poor public speaker. I witnessed this first hand in Vancouver. He is smart, and knows his business, but MUST delegate to a PR person to handle this function for him.
2. Bob failed to announce which US company is working with BIO at the day of the meeting. He lost a lot of momentum by not telling us, and the world.
3. Put trust in his people. I have spoken to the PR man Austin Rand on numerous occasions. More than once, Austin has mentioned that "good" ideas are presented to Bob that are not acted upon. Bob needs to listen to both his people and the shareholders.
Finally, I love the product, and feel our day will come (6-12 months I hope). I still retain over 100,000 shares, but yes I am pissed because I could have sold and re-purchased 2x stock for the same money. That mistake won't happen again, I just thought that the momentum wouldn't have died so fast.
Thx,
Rich |
